Dr. Aiwen Zheng 郑爱文
Chief Physician
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and comprehensive treatment of gynecologic malignancies, including cervical, ovarian, and endometrial cancer, as well as precancerous lesions and pelvic masses.
Dr. Zheng graduated from Hunan Medical University in 1998 and earned a master’s degree in obstetrics and gynecology from Zhejiang University School of Medicine in 2008. As a Chief Physician and medical team leader, Dr. Zheng has led provincial research projects on endometrial and ovarian cancer and published over 20 academic papers.
Professional roles
- Youth Committee Member, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Member, Pelvic Tumor Professional Committee, China Medical Education Association
- Member, Menopause Health Care Professional Committee, Maternal and Child Health Research Association
- Member, Tumor Precision Diagnosis and Treatment Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Zheng Aiwen). Papers usually list the name as Aiwen Zheng or Zheng A.
Selected publications
15 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Discov Oncol, 2025 (senior author): Machine learning modeling and analysis of prognostic hub genes in cervical adenocarcinoma: a multi target therapy for enhancement in immunosurveillance. PubMed 40653567
- J Diet Suppl, 2025 (senior author): Chemoprophylactic Effects of Epigallocatechin Gallate in Female Reproductive Cancers - A Review. PubMed 40518686
- Kaohsiung J Med Sci, 2022 (senior author): MFAP2 aggravates tumor progression through activating FOXM1/β-catenin-mediated glycolysis in ovarian cancer. PubMed 35546486
- Front Immunol, 2021 (senior author): Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms. PubMed 33868290
- Technol Cancer Res Treat, 2021 (senior author): Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience. PubMed 34939467
- Transl Cancer Res, 2020 (first author): Mutational profiling of melanomas in patients from the southeast coast of China. PubMed 35117841
- Oncol Lett, 2017 (first author): Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells. PubMed 28588737
- Biomed Pharmacother, 2017 (first author): Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines. PubMed 28320083
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion